Follow the latest company announcements, clinical research milestones, strategic developments, and updates from Adia Med.
Navigating Idaho regenerative medicine means understanding a regulatory vacuum, the often-misapplied Right to Try Act, and real enforcement cases like the Burst Biologics warning letter. This statewide 2026 guide covers Treasure Valley, Eastern Idaho, and North Idaho, giving patients the regulatory, safety, and insurance context most clinic websites leave out.
This 2026 guide breaks down therapy for sickle cell disease into three clear tiers—supportive care, disease-modifying drugs, and curative options like gene therapy and stem cell transplant. It also covers the latest approvals, safety updates, and pipeline treatments often missing from outdated resources. A practical, up-to-date roadmap for patients and caregivers navigating SCD care.
Facing a choice between Abecma and Carvykti for myeloma CAR T-cell therapy? This data-driven guide breaks down eligibility criteria, response rates, and side-effect profiles for both FDA-approved options. Learn what sets these therapies apart so you can have a more informed conversation with your care team.
Wondering if stem cell therapy for DDD could work for you? This 2026 guide breaks down the four key factors—disc grade, symptom duration, prior treatments, and imaging—that determine candidacy, plus the latest regulatory timeline for rexlemestrocel-L.
A neutral, third-party due-diligence review of Regenerative Medicine of Raynham, examining its legal standing, provider-oversight model, and treatment claims. Designed to help patients make an informed decision before booking a consultation in 2026.
CAR T-cell therapy offers new hope for relapsed multiple myeloma patients, but the journey involves far more than headline trial results. This guide covers the leukapheresis wait, manufacturing timeline, side-effect management, and the true cost of care patients face in 2026.
Peripheral neuropathy affects millions, and many patients turn to stem cell therapy when standard treatments fail. This 2026 evidence review separates documented clinical trial data from preclinical research and unproven commercial claims, noting that no stem cell therapy for peripheral neuropathy is currently FDA-approved.
Stem cell treatment for hair loss is surrounded by hype, but zero options are FDA-approved as of 2026. This guide breaks down the regulatory landscape, compares stem cells to PRP and exosomes, and highlights the real breakthroughs—like UVA’s KROX20+ research and Pelage’s PP405—shaping the field today.
Rise Regenerative Medicine, led by naturopathic physician Dr. Sierra Storm, offers a unique take on regenerative care in Seattle’s Lower Queen Anne. This article breaks down the clinic’s services, philosophy, and what the 2026 regulatory landscape means for patients choosing a provider.
This 2026 guide cuts through hype to explain what degenerative disc disease stem cell therapy can actually do, from disease biology and mechanism of action to clinical trial evidence and FDA regulatory status. Designed for both patients and referring clinicians, it offers a critical, evidence-based framework for evaluating treatment claims before making a decision.
Curious what chimeric antigen receptor T-cell therapy is and how it works? This 2026 guide breaks down the science, the treatment process, and the risks in plain language. Discover why CAR-T therapy has become one of the most groundbreaking advances in modern cancer treatment.
Stem cell therapy for baldness is generating real scientific excitement in 2026, but separating genuine breakthroughs from marketing hype isn’t easy. This article offers a framework for calibrating hope, examining the latest research like the UVA discovery alongside honest timelines and probabilities.
TAKE THE NEXT STEP
Consultations are confidential and conducted by our Orlando-based
clinical staff - for local and international patients alike.
